Market Overview - The Hong Kong stock market opened higher on January 22, with the Hang Seng Index rising by 0.62% to 26,750.51 points, the Hang Seng Tech Index increasing by 0.85% to 5,795 points, and the National Enterprises Index up by 0.55% to 9,173.54 points [1] - Major tech stocks mostly rose, with Alibaba up 1.72%, Tencent Holdings up 0.33%, JD Group up 0.98%, and Xiaomi Group up 0.9% [1] - Chip stocks opened high, with Zhaoyi Innovation rising over 7% [1] - The innovative drug concept was active, with WuXi Biologics rising over 1% [1] - Gold stocks generally fell, with Shandong Gold down over 2% [1] - Longqi Technology's IPO on the Hong Kong stock market saw a nearly 13% increase on its first day [1] Company News - Shanghai Electric (02727.HK) expects a net profit of RMB 1.1 billion to RMB 1.32 billion for 2025, an increase of approximately 47% to 76% year-on-year [2] - Kingdee International (00268.HK) anticipates total revenue of approximately RMB 6.95 billion to RMB 7.05 billion for 2025, a year-on-year growth of about 11.1% to 12.7% [2] - Beijing Machinery Electric (00187.HK) expects a net loss of RMB 46 million to RMB 55.2 million for 2025, primarily due to intensified international trade frictions affecting its gas storage and transportation export business [2] - Chow Tai Fook (01929.HK) reported a retail value growth of 17.8% for the three months ending December 31, 2025, with mainland China retail value increasing by 16.9% [2] - Zai Lab (09911.HK) anticipates a cumulative download of approximately 970 million for its social business by 2025, a year-on-year increase of about 5.9% [2] Strategic Developments - Ruiri Medical Technology (01696.HK) signed a letter of intent for cooperation with Stryker Medical to establish localized production in China [3] - Cathay Pacific (00293.HK) and Hong Kong Express expect to carry over 36 million passengers in 2025, a year-on-year increase of 27% [4] - Shenyang Public Development (00747.HK) has initiated edge computing infrastructure and service business [5] - Flat Glass Group (06865.HK) plans to absorb and merge with Zhongda Quartz Development [6] Share Buybacks - Xiaomi Group (01810.HK) repurchased 7 million shares for HKD 248 million at prices between HKD 35.22 and HKD 35.48 [7] - Pop Mart (09992.HK) repurchased 500,000 shares for HKD 96.49 million at prices between HKD 191.1 and HKD 194.9 [8] - Sunny Optical Technology (02382.HK) repurchased 970,000 shares for HKD 61.39 million at prices between HKD 62.30 and HKD 63.95 [9] - Geely Automobile (00175.HK) repurchased 2.376 million shares for HKD 39.62 million at prices between HKD 16.62 and HKD 16.81 [10] Financial Instruments - Huaneng International Power (00902.HK) completed the issuance of RMB 2 billion medium-term notes [11] - CICC (03908.HK) plans to issue up to RMB 5 billion in bonds for technology innovation companies [12] Institutional Insights - Dongwu Securities noted that despite a general reduction in the Fed's interest rate cut expectations in overseas markets, domestic investors remain optimistic [13] - Orient Securities highlighted that recent U.S. measures against Venezuela and Greenland have increased geopolitical risks, supporting gold prices [14] - Zheshang Securities suggested that the humanoid robot sector has formed an ecological closed loop, recommending attention to component suppliers and undervalued transformation targets [14] - CITIC Securities indicated that new policies from the National Medical Insurance Administration will accelerate the promotion of surgical robots in China [14]

复锐医疗科技(01696)发布公告，公司于2026年1月与星迈泰科医疗科技(北京)有限公司签订合作意向 书，就于中国的本土化潜在合作构建战略合作框架。根据合作意向书，潜在合作拟于中国(集团核心战 略市场之一)建立本土化生产，聚焦于能量源医美设备布局。这是公司践行战略的重要举措，即通过有 效缩短供应链并提升本地市场响应效率来深化以客户为中心的核心战略。此举不仅旨在满足国内需求， 还将为亚太战略枢纽打造区域基石，以满足整个地区对规模化量产、高效物流体系和先进技术日益增长 的需求。 ...

复锐医疗科技(01696)发布公告，公司于2026年1月与星迈泰科医疗科技(北京)有限公司签订合作意向 书，就于中国的本土化潜在合作构建战略合作框架。根据合作意向书，潜在合作拟于中国(集团核心战 略市场之一)建立本土化生产，聚焦于能量源医美设备布局。这是公司践行战略的重要举措，即通过有 效缩短供应链并提升本地市场响应效率来深化以客户为中心的核心战略。此举不仅旨在满足国内需求， 还将为亚太战略枢纽打造区域基石，以满足整个地区对规模化量产、高效物流体系和先进技术日益增长 的需求。 ...

Core Viewpoint - The company, Furuya Medical Technology (01696.HK), has signed a letter of intent with Xingmaitike Medical Technology (Beijing) Co., Ltd. to establish a strategic cooperation framework for localized production in China, focusing on energy source medical aesthetic equipment [1] Group 1: Strategic Initiatives - The potential collaboration aims to establish localized production in China, which is one of the company's core strategic markets [1] - This initiative is part of the company's strategy to shorten the supply chain and enhance local market responsiveness, emphasizing a customer-centric approach [1] Group 2: Regional Impact - The move is intended to meet domestic demand and create a regional foundation for the Asia-Pacific strategic hub [1] - The collaboration addresses the growing demand in the region for scalable mass production, efficient logistics systems, and advanced technology [1]

（ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 自願公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* – 1 – 由於潛在合作取決於是否將訂立任何最終協議，且未必會進行，故本公司股東及 潛在投資者於買賣本公司股份時務請審慎行事。 代表董事會 Sisram Medical Ltd 復銳醫療科技有限公司* 主席 Lior Moshe DAYAN 中國本土化潛在合作 本公告由復銳醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 發佈。 本公司欣然宣佈，本公司於二零二六年一月與星邁泰科醫療科技（北京）有限公司 （「星邁泰科醫療」）簽訂合作意向書（「合作意向書」），就於中華人民共和國（「中 國」）的本土化潛在合作（「潛在合作」）構建戰略合作框架。 根據合作意向書，潛在合作擬於中國（本集團核心戰略市場之一）建立本土化生 產，聚焦於能量源醫美設備佈 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: Sisram Medical Ltd 復銳醫療科技有限公司* 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01696 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | ILS | | 0.01 | ILS | | 10,000,000 | | 增加 / 減少 (-) | | | 0 | | | | ILS | | 0 | | 本月底結存 | | | 1,000,000,000 | ILS | | 0.01 | ILS | ...

每经AI快讯，复锐医疗科技(01696.HK)高开逾4%，截至发稿涨4.55%，报4.6港元，成交额3.86万港元。 ...

公司相信，达希斐作为公司注射填充业务的战略基石，将通过丰富公司产品组合的多样性，为求美者提 供更多优质选择，并将作为第二增长引擎，为公司带来持续性耗材收入，巩固公司在全球美丽健康行业 的领先地位。 消息面上，复锐医疗科技宣布，旗下长效A型肉毒毒素产品达希斐（英文商标DAXXIFY）已正式通过 中国食品药品检定研究院的质量标准检验，标志着达希斐在质量、安全性与有效性方面均符合国家药品 监管体系的严格要求，顺利完成上市前的最终关键环节。 智通财经APP获悉，复锐医疗科技(01696)高开逾4%，截至发稿，涨4.55%，报4.6港元，成交额3.86万港 元。 ...

Core Viewpoint - Furuya Medical Technology (01696) has successfully passed the quality standard inspection for its long-acting botulinum toxin product DAXXIFY, marking a significant milestone for its market entry in China [1] Group 1: Product Development - DAXXIFY has met the stringent quality, safety, and efficacy standards set by the National Medical Products Administration of China, completing the final critical step before market launch [1] - The product is expected to enhance the diversity of the company's injectable filler offerings, providing consumers with more high-quality choices [1] Group 2: Business Impact - DAXXIFY is positioned as a strategic cornerstone for the company's injectable filler business, anticipated to serve as a second growth engine and generate sustainable consumable revenue [1] - The successful launch of DAXXIFY is expected to solidify the company's leading position in the global beauty and health industry [1]

Major Events - Yunzhisheng (09678) secured a regional medical cooperation contract worth over 20 million [1] - Kelun-Biotech (06990) received breakthrough therapy designation from NMPA for TROP2 ADC drug in combination with pembrolizumab for treating PD-L1 positive locally advanced or metastatic non-small cell lung cancer [1] - InSilico Medicine (03696) entered into an 8.88 billion USD multi-year collaboration for anti-tumor drug development with Sihuiya [1] - Hutchison China MediTech (00013) is conducting a Phase III study on surufatinib combined with camrelizumab for first-line treatment of pancreatic ductal adenocarcinoma [1] - Ascletis Pharma-B (01672) announced FDA approval for IND of ASC30 in a 13-week Phase II study in diabetic patients [1] - Foryou Medical (01696) received quality standard inspection approval for its reauthorized injectable botulinum toxin from the Chinese National Medical Products Administration [1] - CanSino Biologics (06185) obtained clinical trial approval in China for its 24-valent pneumococcal polysaccharide conjugate vaccine [1] - Stone Group (02005) received drug production registration approval for perindopril and amlodipine tablets [1] - Sunny Optical Technology (02382) proposed to spin off its automotive optical business for independent listing on the Hong Kong Stock Exchange [1] - Dongyang Sunshine Pharmaceutical (06887) completed the first patient enrollment for HECN30227 in China [1] - Haitong International's subsidiary plans to sell 100% equity of Guohua Machinery for 342 million [1] - Yuexiu Property (00123) subsidiary intends to sell 73.74% actual equity in Hangzhou Yueyun [1] - CIMC Group (02039) subsidiary CIMC Shilianda plans to introduce strategic investors through capital increase and transfer of a small number of old shares [1] Operating Performance - Chifeng Jilong Gold Mining (06693) expects annual net profit attributable to shareholders to be approximately 3 billion to 3.2 billion, an increase of about 70% to 81% year-on-year [2] - Corning Hospital (02120) anticipates outpatient visits to reach approximately 720,200 in 2025, a year-on-year increase of 29% [2] - Seres (09927) reported total vehicle sales of 63,700 units in December, a year-on-year increase of 53.54% [2] - Xiehe New Energy (00182) reported an equity power generation of 790.32 GWh in December [2] - Country Garden (02007) reported contract sales amounting to approximately 2.69 billion attributable to shareholders in December [2]